Your browser doesn't support javascript.
loading
Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis.
Steinberg, Julia; Hughes, Suzanne; Hui, Harriet; Allsop, Matthew J; Egger, Sam; David, Michael; Caruana, Michael; Coxeter, Peter; Carle, Chelsea; Onyeka, Tonia; Rewais, Isabel; Monroy Iglesias, Maria J; Vives, Nuria; Wei, Feixue; Abila, Derrick Bary; Carreras, Giulia; Santero, Marilina; O'Dowd, Emma L; Lui, Gigi; Tolani, Musliu Adetola; Mullooly, Maeve; Lee, Shing Fung; Landy, Rebecca; Hanley, Sharon J B; Binefa, Gemma; McShane, Charlene M; Gizaw, Muluken; Selvamuthu, Poongulali; Boukheris, Houda; Nakaganda, Annet; Ergin, Isil; Moraes, Fabio Ynoe; Timilshina, Nahari; Kumar, Ashutosh; Vale, Diama B; Molina-Barceló, Ana; Force, Lisa M; Campbell, Denise Joan; Wang, Yuqing; Wan, Fang; Baker, Anna-Lisa; Singh, Ramnik; Salam, Rehana Abdus; Yuill, Susan; Shah, Richa; Lansdorp-Vogelaar, Iris; Yusuf, Aasim; Aggarwal, Ajay; Murillo, Raul; Torode, Julie S.
Afiliación
  • Steinberg J; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Hughes S; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Hui H; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Allsop MJ; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Egger S; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • David M; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Caruana M; School of Medicine and Dentistry, Griffith University, Gold Coast, Australia.
  • Coxeter P; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Carle C; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Onyeka T; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Rewais I; Department of Anaesthesia/Pain & Palliative Care Unit, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria.
  • Monroy Iglesias MJ; IVAN Research Institute, Enugu, Nigeria.
  • Vives N; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Wei F; Translational Oncology and Urology Research (TOUR), Centre for Cancer, Society, and Public Health, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Abila DB; Cancer Screening Unit, Institut Català d'Oncologia (ICO), Early Detection of Cancer Group, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Carreras G; Ciber Salud Pública (CIBERESP), Instituto Salud Carlos III, Madrid, Spain.
  • Santero M; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.
  • O'Dowd EL; Makerere University College of Health Sciences, Kampala, Uganda.
  • Lui G; Oncologic Network, Prevention and Research Institute (ISPRO), Florence, Italy.
  • Tolani MA; Iberoamerican Cochrane Centre, IIB Sant Pau-Servei d'Epidemiologia Clínica i Salut Pública, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Mullooly M; Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Lee SF; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Landy R; Department of Surgery, Ahmadu Bello University, Zaria, Nigeria.
  • Hanley SJB; School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
  • Binefa G; Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore.
  • McShane CM; Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hospital Authority, Hong Kong, China.
  • Gizaw M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Selvamuthu P; Department of Academic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland.
  • Boukheris H; Center for Environmental and Health Sciences, Hokkaido University, Sapporo, Japan.
  • Nakaganda A; Cancer Screening Unit, Cancer Prevention and Control Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
  • Ergin I; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Barcelona, Spain.
  • Moraes FY; Centre for Public Health, Queen's University Belfast, Institute of Clinical Sciences Block B, Royal Victoria Hospital, Belfast, Northern Ireland.
  • Timilshina N; Department of Preventive Medicine, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.
  • Kumar A; Institute for Medical Epidemiology, Biometrics and Informatics, Martin Luther University of Halle-Wittenberg, Halle, Germany.
  • Vale DB; NCD Working Group, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.
  • Molina-Barceló A; Chennai Antiviral Research and Treatment Center and Clinical Research Site (CART CRS), Infectious Diseases Medical Center, Voluntary Health Services, Chennai, India.
  • Force LM; University Abderrahmane Mira of Bejaia, School of Medicine, Bejaia, Algeria.
  • Campbell DJ; Department of Epidemiology and Preventive Medicine, University Hospital of Bejaia, Bejaia, Algeria.
  • Wang Y; Department of Cancer Epidemiology and Clinical Trials, Uganda Cancer Institute, Kampala, Uganda.
  • Wan F; Department of Public Health, Faculty of Medicine, Ege University, Bornova, Turkey.
  • Baker AL; Department of Oncology, Queen's University, Kingston, Ontario, Canada.
  • Singh R; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Salam RA; Department of Anatomy, All India Institute of Medical Sciences-Patna, Patna, India.
  • Yuill S; Department of Obstetrics and Gynecology, University of Campinas (UNICAMP), Campinas, Brazil.
  • Shah R; Cancer and Public Health Research Unit, Biomedical Research Foundation FISABIO, Valencia, Spain.
  • Lansdorp-Vogelaar I; Department of Health Metrics Sciences, Division of Hematology/Oncology, University of Washington, Seattle, Washington, USA.
  • Yusuf A; Department of Pediatrics, Division of Hematology/Oncology, University of Washington, Seattle, Washington, USA.
  • Aggarwal A; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
  • Murillo R; School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
  • Torode JS; School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
Int J Cancer ; 154(8): 1394-1412, 2024 Apr 15.
Article en En | MEDLINE | ID: mdl-38083979
ABSTRACT
While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed/treated cancer (general population aOR = 1.48, 95% CI 1.36-1.61, I2 = 0; people with COVID-19 aOR = 1.58, 95% CI 1.41-1.77, I2 = 0.58; inpatients with COVID-19 aOR = 1.66, 95% CI 1.34-2.06, I2 = 0.98). Risks were more elevated for lung (general population aOR = 3.4, 95% CI 2.4-4.7) and hematological cancers (general population aOR = 2.13, 95% CI 1.68-2.68, I2 = 0.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI 1.37-1.75) at 1 year and aOR = 0.98 (95% CI 0.80-1.20) at 5 years post-cancer diagnosis/treatment. In conclusion, before COVID-19-vaccination, risk of COVID-19-related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 / Neoplasias Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Int J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 / Neoplasias Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Int J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Australia